W.H. Sutherland

Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States

Daniel B. Mark, C. David Naylor, Mark A. Hlatky et al. · New England Journal of Medicine · 1994 · 348 citations

Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients

Jérôme Alexandre, Pascal Bleuzen, Jacques Bonneterre et al. · Journal of Clinical Oncology · 2000 · 79 citations

MACROPHAGE-ELECTROPHORETIC-MOBILITY (M.E.M.) TEST FOR MALIGNANT DISEASE

J A Pritchard, W.H. Sutherland, John L. Moore et al. · The Lancet · 1972 · 70 citations

Medicine, Immunology, Histopathology +6

Evaluation and Development of the Macrophage Electrophoretic Mobility (MEM) Test for Malignant Disease)

J A Pritchard, John L. Moore, W.H. Sutherland et al. · British Journal of Cancer · 1973 · 62 citations

Histopathology, Immunology, Pathology +4

Technical aspects of the macrophage electrophoretic mobility (MEM) test for malignant disease.

J A Pritchard, John L. Moore, W.H. Sutherland et al. · PubMed · 1973 · 34 citations

Vitro Blood Test, Oncology, Confirmatory Evidence +15